pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Gene Therapy (AAV) · news · pharmadog
← back to Gene Therapy (AAV)
News · Gene Therapy (AAV)
217
stories
10d
Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
biopharma dive
10d
BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication
biospace
11d
From ex vivo to in vivo: Shaping the next generation of viral vector manufacturing
biospace
13d
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
biospace
13d
Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy
fiercebiotech
14d
STAT+: Two FDA approvals — a new drug and a new vaccine
stat
14d
FDA approves Moderna’s mRNA flu vaccine
biopharma dive
15d
CROs vs. biotechs: Finding the right fit
biospace
15d
STAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety
stat
15d
Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employees
biospace
15d
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
biospace
16d
Lilly drops another gene therapy trial from $1B Prevail buyout
fiercebiotech
16d
Fresenius Kabi Issues Voluntary Nationwide Recall of One Lot of Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe Due to Labeling Mix-up
fda medwatch
16d
J&J pharma leader to retire; Krystal slumps on gene therapy miss
biopharma dive
18d
Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacity
biospace
18d
5 companies advancing ATTR assets in the wake of Wainua’s fail
biospace
20d
Capricor CEO won’t rule out legal action against FDA after negative adcomm
biospace
20d
UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma
biospace
21d
Opinion: Limb girdle muscular dystrophy patients face a maddening reality
stat
21d
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
biospace
22d
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
22d
FDA advisers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting
biospace
22d
FDA reviewers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting
biospace
22d
Capricor Duchenne cell therapy voted down by FDA panel
biopharma dive
22d
FDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute
fiercebiotech
23d
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
24d
STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
stat
24d
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
biospace
24d
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
biopharma dive
24d
STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive
stat
← prev
page 2 of 8
next →
